Publication Venue For
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
Risk of second primary cancers among survivors of gynecological cancers
Human papillomavirus: The other invisible enemy
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis
Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES)
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II
Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Extensive financial hardship among gynecologic cancer patients starting a new line of therapy
Human papillomavirus vaccination: Ongoing challenges and future directions
Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers
Corrigendum to ‘Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer’ [Gynecologic Oncology 157 (2020) 765–774] (Gynecologic Oncology (2020) 157(3) (765–774), (S0090825820302262), (10.1016/j.ygyno.2020.03.010))
Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer
Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide
Corrigendum to “Financial toxicity – An overlooked side effect” (Gynecologic Oncology (2018) 150(1) (3–6), (S0090825818308990), (10.1016/j.ygyno.2018.05.012))
Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population
Gynecologic oncology providers endorse practice-changing impact of communication skills training
The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer
The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction
Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman
Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey
Endometrial cancer: Molecular markers and management of advanced stage disease
Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years
Financial toxicity – An overlooked side effect
Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication
Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study
Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic
Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
Values and worries of ovarian cancer patients
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study
The impact of physician burnout on clinical and academic productivity of gynecologic oncologists: A decision analysis
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma – A multi-institutional cohort
Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
Effectiveness of cyanoacrylate microbial sealant in the reduction of surgical site infection in gynecologic oncology procedures: A phase III single institution prospective randomized trial
Early warning score: An indicator of adverse outcomes in postoperative patients on a gynecologic oncology service
Ovarian cancer and the immune system — The role of targeted therapies
Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)
Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?
Metabolic risk factors and mechanisms of disease in epithelial ovarian cancer: A review
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma
Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer
Use of primary high-risk human papillomavirus testing for cervical cancer screening: Interim clinical guidance
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?
Evaluation of in vitro chemoresponse profiles in women with Type i and Type II epithelial ovarian cancers: An observational study ancillary analysis
Ovarian and cervical cancer patient derived xenografts: The past, present, and future
Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial
Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection
Teaching gynecologic oncology in Low resource settings: A collaboration of health volunteers overseas and the society of gynecologic oncology
Validation of a venous thromboembolism risk assessment model in gynecologic oncology.
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study
A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
Black race independently predicts worse survival in uterine carcinosarcoma
Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients
Diabetes mellitus and ovarian cancer: More complex than just increasing risk
Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer
Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma
Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center
Reducing readmissions after robotic surgical management of endometrial cancer: a potential for improved quality care.
The Wnt/β-catenin pathway in ovarian cancer: A review
Erratum: HPV vaccination in women treated for CIN2/3: It's still all about prevention (Gynecologic Oncology (2013) 130 (255-256))
Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer
A phase i clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis
Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?
HPV vaccination in women treated for CIN2/3: It's still all about prevention
Low yield of residual vulvar carcinoma and dysplasia upon re-excision for close or positive margins
Chemotherapy for advanced and recurrent cervical carcinoma: Results from cooperative group trials
The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival
Incidence of port site hernias and/or dehiscence in robotic-assisted procedures in gynecologic oncology patients
Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors
Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility
Re: "The utilization of palliative care in gynecologic oncology patients near the end of life".
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
The utilization of palliative care in gynecologic oncology patients near the end of life.
Management of complex pelvic masses using a multivariate index assay: A decision analysis
Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy
Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion
The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells
Does economic burden influence quality of life in breast cancer survivors?
Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells
Evaluation of the Patient-Generated Subjective Global Assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: a pilot study.
Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies
A cohort study evaluating robotic versus laparotomy surgical outcomes of obese women with endometrial carcinoma
Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence.
Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer
Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines
Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation.
Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model
Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening
Long-term outcome and natural history of uterine adenosarcomas
Overcoming TRAIL resistance in ovarian carcinoma
Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and interventions.
Overcoming the barriers to HPV vaccination in high-risk populations in the US
What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus
Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy.
How does public policy impact cervical screening and vaccination strategies?
Extragenital adenosarcoma: A case report, review of the literature, and management discussion
An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC)
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer
Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes
The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies.
The effect of obesity on survival in patients with ovarian cancer
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer
Corrigendum to "The current and future role of screening in the era of HPV vaccination" [Gynecol. Oncol. 109 (2008) S31-S39] (DOI:10.1016/j.ygyno.2008.02.001)
Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer
Age considerations when vaccinating against HPV
Initial lessons learned in HPV vaccination
The disparity of cervical cancer in diverse populations
The future of vaccines for cervical cancer
Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model
Oncolytic adenovirus Ad5/3-Δ24 and chemotherapy for treatment of orthotopic ovarian cancer
The current and future role of screening in the era of HPV vaccination
Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary
Primitive neuroectodermal tumor of the myometrium with cardio-vascular symptoms
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers
Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report.
A multi-institutional review of outcomes of endometrial stromal sarcoma
Fertility-sparing radical abdominal trachelectomy for clear cell adenocarcinoma of the upper vagina: A case report
Anemia correction in malignancy management: Threat or opportunity?
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model
A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy
Primary appendiceal cancer: Gynecologic manifestations and treatment options
Fertility sparing therapy in a patient with placental site trophoblastic tumor: A case report
Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision
Unilateral cervical cancer in a patient with cervix duplex
Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer
Recurrent basosquamous cell carcinoma of the vulva
Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model
Carcinosarcoma of the ovary - A case series
Re: "outcomes of stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy"  (multiple letters)
Optical detection of cervical neoplasia: results from an internally-controlled multicenter study.
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC)
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: A patient care evaluation study from the American College of Surgeons National Cancer Data Base
A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses
Predictors of outcomes for women with cervical carcinoma
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent
Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies.
Gamma mode of infiltration associated with poor prognosis in malignant teratoma of the ovary: A case report
Adenoviruses with an RGD-4C modification of the fiber knob elicit a neutralizing antibody response but continue to allow enhanced gene delivery
Immune responses to human papillomavirus in genital tract of women with cervical cancer
A case report of rhabdomyosarcoma of the uterus associated with uterine inversion
Management strategies for stage IB2 cervical cancer: A cost-effectiveness analysis
Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy
Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy
The impact of aborted radical hysterectomy in patients with cervical carcinoma
Infectivity enhanced adenoviral-mediated mda-7/IL-24 gene therapy for ovarian carcinoma
Primary lung large cell carcinoma metastatic to the vulva: A case report and review of the literature
Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer
The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation
Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy
Complications of indwelling venous access devices in patients with gynecologic malignancies
Uterine papillary serous carcinoma: Comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy
A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis
Conservative management of Stage I endometrial carcinoma after surgical staging
Treatment preferences in recurrent ovarian cancer
A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts
An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites
Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix
Genetic origin of malignant trophoblastic neoplasms analyzed by sequence tag site polymorphic markers
Immunohistochemical expression of molecular markers in an avian model: A potential model for preclinical evaluation of agents for ovarian cancer chemoprevention
Predictors of outcome in small cell carcinoma of the cervix - A case series
Transcriptional targeting for ovarian cancer gene therapy
A patient presenting with a pelvic mass, elevated CA-125, and fever
An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type I vector
An umbilical metastasis after laparoscopy for squamous cell carcinoma of the cervix
Intraperitoneal radioimmunotherapy of ovarian cancer with
Lu- CC49: A phase I/II study
Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy
Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbb-2 single-chain antibody
Intracranial metastases from carcinoma cervix and review of literature
Coexisting intraductal breast carcinoma and metastatic choriocarcinoma presenting as a breast mass
Establishment and characterization of a human cell line from a serous papillary endometrial carcinoma
Intraperitoneal chromic phosphate in ovarian cancer: Risks and benefits
Endometrial stromal cells in culture: An attempt to understand the genesis and biologic activity of uterine sarcomas
Genital aerobic bacterial flora of women receiving radiotherapy for gynecologic malignancy
An extra-adrenal pheochromocytoma mimicking lymph node metastasis from a cervical cancer
International Standard Serial Number (issn)
Electronic International Standard Serial Number (eissn)